Arvinas (ARVN)
(Delayed Data from NSDQ)
$24.94 USD
-0.04 (-0.16%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $24.93 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ARVN 24.94 -0.04(-0.16%)
Will ARVN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARVN
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View
ARVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
Acadia (ACHC), Geisinger JV Begin Construction of New Hospital
Other News for ARVN
Arvinas participates in a conference call hosted by Truist
Analysts Conflicted on These Healthcare Names: BioLife Solutions (BLFS), Arvinas Holding Company (ARVN) and Natera (NTRA)
Arvinas Holding Company (ARVN) Receives a Buy from Stifel Nicolaus
Analysts Have Conflicting Sentiments on These Healthcare Companies: Teladoc (TDOC), Arvinas Holding Company (ARVN) and Jazz Pharmaceuticals (JAZZ)
Truist Financial Keeps Their Buy Rating on Arvinas Holding Company (ARVN)